TELA Bio annual operating margin
2017
2018
2019
2020
2021
2022
2023
2024
2025
TELA Bio's operating margin was −42.05% for fiscal 2025.
View full TELA Bio company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −42.05% | +7.18 pp |
| 2024 | 2024-12-31 | −49.23% | +26.17 pp |
| 2023 | 2023-12-31 | −75.40% | +18.78 pp |
| 2022 | 2022-12-31 | −94.18% | +5.78 pp |
| 2021 | 2021-12-31 | −99.96% | +38.82 pp |
| 2020 | 2020-12-31 | −138.77% | −14.72 pp |
| 2019 | 2019-12-31 | −124.06% | +90.86 pp |
| 2018 | 2018-12-31 | −214.91% | +183.77 pp |
| 2017 | 2017-12-31 | −398.68% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −48.12% | −3.16 pp |
| Q1 2026 | 2026-03-31 | −55.23% | +1.32 pp |
| Q4 2025 | 2025-12-31 | −31.86% | +15.48 pp |
| Q3 2025 | 2025-09-30 | −36.51% | +12.89 pp |
| Q2 2025 | 2025-06-30 | −44.96% | +26.94 pp |
| Q1 2025 | 2025-03-31 | −56.54% | −27.48 pp |
| Q4 2024 | 2024-12-31 | −47.33% | +24.90 pp |
| Q3 2024 | 2024-09-30 | −49.40% | +18.24 pp |
| Q2 2024 | 2024-06-30 | −71.90% | −0.41 pp |
| Q1 2024 | 2024-03-31 | −29.07% | +65.43 pp |
| Q4 2023 | 2023-12-31 | −72.23% | +8.98 pp |
| Q3 2023 | 2023-09-30 | −67.64% | +17.38 pp |
| Q2 2023 | 2023-06-30 | −71.49% | +26.88 pp |
| Q1 2023 | 2023-03-31 | −94.50% | +25.10 pp |
| Q4 2022 | 2022-12-31 | −81.22% | +10.19 pp |
| Q3 2022 | 2022-09-30 | −85.02% | +9.27 pp |
| Q2 2022 | 2022-06-30 | −98.38% | −1.64 pp |
| Q1 2022 | 2022-03-31 | −119.60% | +4.09 pp |
| Q4 2021 | 2021-12-31 | −91.40% | +27.66 pp |
| Q3 2021 | 2021-09-30 | −94.29% | +34.88 pp |
| Q2 2021 | 2021-06-30 | −96.73% | +50.57 pp |
| Q1 2021 | 2021-03-31 | −123.69% | +50.74 pp |
| Q4 2020 | 2020-12-31 | −119.06% | +0.72 pp |
| Q3 2020 | 2020-09-30 | −129.17% | −32.12 pp |
| Q2 2020 | 2020-06-30 | −147.31% | −17.12 pp |
| Q1 2020 | 2020-03-31 | −174.42% | −17.74 pp |
| Q4 2019 | 2019-12-31 | −119.78% | −5.67 pp |
| Q3 2019 | 2019-09-30 | −97.06% | — |
| Q2 2019 | 2019-06-30 | −130.18% | — |
| Q1 2019 | 2019-03-31 | −156.68% | — |
| Q3 2018 | 2018-09-30 | −114.10% | — |
Over the last five reported fiscal years, TELA Bio's operating margin increased from −138.77% to −42.05%, a change of +96.73 percentage points. The latest reported quarter, Q2 2026, shows −48.12%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review TELA Bio filings at SEC.gov ↗